BioCentury | Jan 11, 2017
Distillery Therapeutics

Neurology

...matter stroke, a chimeric RTN4R-RTN4RL2-Fc fusion protein that inhibits the Nogo signaling ligands MAG , OMG...
...receptor (RTN4R; NGR); reticulon 4 receptor-like 2 (RTN4RL2; NgR2); myelin associated glycoprotein (MAG); oligodendrocyte myelin glycoprotein (OMG; OMGP...
...Medicine at UCLA, Los Angeles, Calif. email: scarmichael@mednet.ucla.edu Winnie Pong University of California Los Angeles Myelin associated glycoprotein (MAG) Oligodendrocyte myelin glycoprotein (OMG) (OMGP) Reticulon...
BioCentury | Apr 15, 2013
Company News

Oxford Molecular, MLR Automation deal

...see B19). OMG paid $75,000 upfront, and will pay the balance upon finalizing the agreement. OMG...
...had pre-tax profits of $77,000 on revenues of $316,000 last year. Oxford Molecular Group PLC (LSE:OMG...
BioCentury | Apr 15, 2013
Company News

Oxford Molecular, Genetics Computer Group Inc. deal

...OMG plans to finance the acquisition through a 1 for 7 rights issue (see B19). OMG...
...pre-tax profits of $132,000 on revenues of $3.1 million last year. Oxford Molecular Group PLC (LSE:OMG...
BioCentury | Apr 15, 2013
Company News

Oxford Molecular, Astra Group AB deal

...Astra’s Astra Arcus AB subsididary (Sodertajle) and OMG will develop an integrated set of desktop software...
...discovery process. The companies plan to complete the project in a year, after which time OMG...
...be allowed to use the software at its research locations worldwide. Oxford Molecular Group PLC (LSE:OMG...
BioCentury | Apr 15, 2013
Company News

Oxford Molecular other research news

...A European consortium led by OMG received a £450,000 (US$756,000) Eureka grant from the U.K. Department...
...Astra, Silicon Graphics, Trinity College Dublin, Nottingham University and Turku University. Oxford Molecular Group PLC (LSE:OMG...
BioCentury | Sep 27, 2010
Emerging Company Profile

Axerion: Going beyond NOGO

...4 ( RTN4 ; NOGO-A ; NOGO ), myelin associated glycoprotein (MAG) and oligodendrocyte myelin glycoprotein (OMG; OMGP...
...NGR-Fc fusion protein. The molecule acts as a decoy NGR, mopping up NOGO, MAG and OMG...
...showed a smaller increase in axon growth and behavioral recovery, and mice lacking MAG and/or OMG...
BioCentury | May 27, 2010
Distillery Therapeutics

Indication: Neurology

...Neurology Spinal cord injury (SCI) Reticulon 4 (RTN4; NOGO-A; NOGO); myelin-associated glycoprotein (MAG); oligodendrocyte myelin glycoprotein (OMG; OMGP...
...4 receptor (RTN4R; NGR) In vitro and mouse studies suggest that simultaneous inhibition of MAG, OMGP...
...Omgp, mice lacking Nogo-A or wild-type mice. In a mouse SCI model, animals lacking Nogo-A, Omgp...
BioCentury | Dec 4, 2008
Cover Story

New strategies for CNS regeneration

...receptor B (PirB), bound multiple axonal growth inhibitors, including NOGO-A, myelin-associated glycoprotein (MAG) and oligodendrocyte myelin glycoprotein (OMG...
...myelin-associated ligands, including reticulon 4 ( RTN4 ; NOGO-A ), myelin-associated glycoprotein (MAG) and oligodendrocyte myelin glycoprotein (OMG).Previous...
BioCentury | Sep 11, 2000
Company News

Oxford Molecular, Pharmacopeia deal

...PCOP completed its acquisition of OMG bioinformatics and cheminformatics software subsidiaries Oxford Molecular Ltd., Chemical Holding...
...Group Inc. for $27 million in cash (see BioCentury, Aug. 14). Oxford Molecular Group plc (LSE:OMG...
BioCentury | Aug 14, 2000
Finance

Some warning signs

...and CEO of Oxford Molecular (LSE:OMG), now will have more time to pursue his hobby. OMG...
...cash payout of 41p-44p a share, with a view to winding up the whole company. OMG...
Items per page:
1 - 10 of 94